Honoured to receive the 🏅 Best Poster Presentation award 🏅at the #EASL #SLDSummit 2026 in Budapest 🇭🇺
A great opportunity to present and discuss data on platelet behaviour in #MASLD within an international scientific setting. Many thanks to all collaborators! 🙌
Presented data from my study at the #EASL #SLDSummit 2026 in Budapest 🇭🇺
I shared insights on #platelet activation and function 🧪 across different stages of #MASLD
A valuable opportunity for discussion and scientific exchange ✨️
📢 I’ve got wonderful news to share! 🏆 My abstract was accepted for @EASLnews #SLDSummit 2026! I’m looking forward to sharing my research 🧪🔬🩺in Budapest 🇭🇺 from 26-28 February. Register to join me there➡️https://easl.eu/sld2026
Last week Vicki took to the stage to deliver a powerful message: empower patients and break the stigma surrounding chronic diseases like obesity, diabetes, and severe liver diseases at the #SLDSummit, highlighting patients are "disease specialists" in their own conditions.
#AddressingObesityTogether
Wonderful to present my project on prevalence of ceruloplasmin in patients with alcohol-use disorder @easlnews.bsky.social #SLDSummit
Excellent talk by @luisantoniodiaz.bsky.social on public health policies and MASLD/outcomes 👌
✅ Policies on healthy eating, diabetes, and cardiovascular disease are associated with improved outcomes and should be prioritized
@easlnews.bsky.social #liversky #SLDSummit #PublicHealth #GlobalHealth
From Dr Frank Murray:
♦️Alcohol is a major global problem ➡️ years of life lost
♦️⚠️Labels—cancer risk!
♦️Need for public health interventions: 🚫 ads, ⬆️ price, tax, implement POLICIES
♦️Challenges: powerful 🍸 lobbies
✅We need to 📣 for evidence-based policies!
@easlnews.bsky.social #liversky #SLDSummit
From Dr Frank Murray:
♦️Alcohol is a major global problem ➡️ years of life lost
♦️⚠️Labels—cancer risk!
♦️Need for public health interventions: 🚫 ads, ⬆️ price, tax, implement POLICIES
♦️Challenges: powerful 🍸 lobbies
✅We need to 📣 for evidence-based policies!
@easlnews.bsky.social #liversky #SLDSummit
🔹Lots of hormone dysregulation in SLD, especially insulin and glucagon
🔹Gut hormones play important roles (GLP, GIP)
🔹Thyroid hormones are also implicated
🔹Lots of drug targets with an exciting future ahead for patients with MASLD!
@easlnews.bsky.social #SLDSummit #liversky
🔸MASLD is 📈 in pediatrics
🔸Not all steatosis in 🧒 is MASLD (inborn errors of metabolism)
🔸Gestational DM, PNPLA3, parental obesity ⬆️ risk, w/ PNPLA3 associated w/ advanced fibrosis risk
🔸🚫 fructose🥤
🔸⬆️BMI in 🧒 🔀 cirrhosis/HCC as 🧑
#liversky #pediatricsky #medsky @easlnews.bsky.social #SLDSummit
Great talk by YI E. Torrejón on how gut EV-kupffer cell interaction contributes to MASLD #SLDsummit
HFD gut-EVs carry Selenocysteine Lyase (SCLY) to Kupffer cells, attenuating pro-inflammatory activity. It also activates ZEB2, inhibiting fibrogenesis
@easlnews.bsky.social
Stijn Meijnikman on the role of auto-brewery 🍺🦠 in SLD
The goal for the future is to use personalised medicine to eliminate high-ethanol-producing bacteria (gut microbiota transplantation, phages, antibiotics, pre|probiotics)
@easlnews.bsky.social #SLDsummit @debbieshawcross.bsky.social #Liversky
Martinez-Chantar addresses potential mitochondria-targeting therapies in MASLD, focusing on:
🎯 Methylation-controlled J protein (MCJ)
🎯 Glutaminase 1 (GLS1)
🎯 Mg2+ transporter CNNM4
using GalNAc-siRNA conjugates 💉
@easlnews.bsky.social #SLDsummit #Liversky
👌 talk on extraheatic complications of MASLD
MASLD & metabolic disease are 🔗, w/📈 severity of MASLD correlates w/ severity of metabolic disease & MACE.
Both 🔗 & causality: patients w/ MASLD have different phenotypes w/ implications for treatment and personalized medicine #liversky #SLDSummit
@rautoupe.bsky.social provides an update on endothelium-platelet interactions in SLD:
🎯 LSEC capillarisation increases with liver fibrosis in MASLD
🎯 Aspirin improves MASLD
🎯 Likely by inhibiting platelet accumulation and/or platelet EV release
@easlnews.bsky.social #SLDSummit
@EASLnews.bsky.social in #Estoril 🇵🇹 from 2004 1️⃣st #NAFLD Monothematic Conference to 2025 #SLDsummit. Same place, same subject, 21 years apart. Time flies, #liver biopsy🔬remains central for steatohepatitis dx! @myueg.bsky.social @liverpath.bsky.social @aasld-heptoxsig.bsky.social
Young Investigator Poster Tour @easlnews.bsky.social #SLDSummit
Huge attendance and interest! 👏🏼
@tom-marjot.bsky.social @madsisraelsen.bsky.social
Alcohol use disorders increase after bariatric surgery. Why?
🎯 Increased consumption, sure, but also:
🎯 Alcohol pharmacokinetics
🎯 Gut hormone secretion changes
Anja Geerts @easlnews.bsky.social #SLDSummit #liversky
The first Young Investigator selected talk @ the #SLDSummit is pure basic science 😍
Erika Paolini used spatial transcriptomics to map the metabolic zonation of hepatocytes in MASLD, showing that PNPLA3 affects zonation by impairing periportal function
🧫🔬⚗️🧬🧪
@easlnews.bsky.social #liversky
There is still a lot of debate on the fatty liver disease / SLD nomenclature change, almost 2 years after endorsement by the leading Hepatology societies.
Philip Newsome reflects on the importance to keep discussing the reasoning behind this change
@easlnews.bsky.social #SLDSummit #liversky
@easlnews.bsky.social #SLDSummit kick-off! 🏃🏻♂️➡️⚽️
Introductory session & welcoming by the organisers
Helena Cortez-Pinto, Christophe Moreno, Bart Staels & Gema Martinez
Fantastic day of learning from the best of the best of #liversky with @luisantoniodiaz.bsky.social @majathiele.bsky.social @juanpabloarab.bsky.social and many more @easlnews.bsky.social #SLDSummit
Great #liver programme today, lively discussions at the 4th Hepatology 🩺🔬Pathology Symposium 👌organised by @docberza.bsky.social and Matteo Montani in Bern 🇨🇭🙏! Off to #Estoril 🇵🇹now for the mighty 2️⃣0️⃣th #SLDsummit! @easlnews.bsky.social
The 🌎 burden of #MASH is staggering: 5.3% of adults face higher risks of cirrhosis, liver cancer & other complications as fibrosis progresses.
our latest study on MAESTRO-NASH resmetirom data & its real-world implications post-FDA approval www.nature.com/articles/s44... #SLDsummit
Excellent talk by THE @majathiele.bsky.social on finding fibrosis in the population.
🔑 Find the patients where they are and use the tests that you have at hand
#SLDSummit @easlnews.bsky.social
Dr @aleksanderkrag.bsky.social kicks off the #SLDsummit. First session is the SLD patient trajectory, proud to have contributed to it. We're joining after a fabulous visit to the Portuguese diabetes centre in Lisbon yesterday...
@easlnews.bsky.social
🚀Excited to share my groundbreaking research for #EASL #SLDSummit 2025 in Estoril 🇵🇹 from 23-25 January 🔬 Join me in advancing the fight against steatotic liver disease. Let's make a difference together! 🌟Register for the summit now: ctt.ec/wqm_y+
The EASL #SLDSummit 2025 Abstract Book is now available🔥
Browse the accepted abstracts and find out what is new and emerging in this field now: easl.eu/event/easl-s...
See you in Estoril on 23-25 January!
I'm very much looking forward to the EASL #SLDsummit in 2 weeks. We have an oral on MASLD #BestBuys, 2 posters on #MASHcities and one on the cost of Inaction. I'll also chair the #publichealth session - don't miss it. #LiverSky
Are you joining us at the EASL #SLDSummit 2025?
📅 23 - 25 January, Estoril, Portugal & Online
👉You are still in time to register: easl.eu/event/easl-s...
👉 Check the programme: easl.eu/event/easl-s...
